# Henry Schein Inc. (HSIC) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Providers & Services. Price $89.81, market value $10.0 billion.

## Valuation
- **P/E (trailing): 26.2×** (5-yr avg 21.5×, 3-yr avg 23.4×). Henry Schein Inc. trades at 26.2× trailing earnings, well above its own five-year average of 21.5×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 2.08**. A PEG of 2.08 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 0.7×**. Each dollar of revenue is priced at 0.7×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 3.2×**. The shares trade at 3.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 10.7×**. Enterprise value is 10.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.7%** (5-yr avg 5.6%). Free cash flow equals 5.7% of the market value, in line with its five-year average of 5.6%. Above 5% is generally attractive.
- **Earnings yield: 3.8%**. The inverse of the P/E: 3.8% of the price is earned each year.

## Profitability
- **Gross margin: 31.3%**. Henry Schein Inc. keeps 31.3% of revenue after the direct cost of what it sells.
- **Operating margin: 5.0%**. 5.0% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 3.0%**. 3.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 12.3%**. 12.3% on shareholders' equity is solid.
- **Return on invested capital: 13.4%**. Return on all capital, debt included, is 13.4%.
- **Return on assets: 3.6%**. Each dollar of assets produces 3.6% of profit.

## Growth
- **Revenue growth (1 yr): 4.0%** (3-yr 1.4%/yr, 5-yr 5.4%/yr). Revenue grew 4.0% over the last year, against 5.4% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 7.2%** (3-yr -5.8%/yr, 5-yr 3.0%/yr). Earnings per share rose 7.2%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 4.2%/yr**. Free cash flow has compounded at 4.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.24**. Debt is 0.24 times equity: a conservative balance sheet.
- **Current ratio: 1.38** (quick 1.38). Current assets cover the next year's liabilities 1.38 times.
- **Altman Z-score: 2.84**. A Z-score of 2.84 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Henry Schein Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover Henry Schein Inc.; the consensus is buy, with an average price target of $98.19 (+9% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 32.5%** (YTD 18.8%, 3-mo 16.0%). The shares are up 32.5% over twelve months including dividends.
- **From 52-week high: -2.6%** (45.0% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 0.56** (volatility 26%). Beta of 0.56 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=HSIC · Page: https://foliofundamentals.com/stocks/hsic

Not investment advice.